Discrimination of Free Space and Subsurface Canonical Metallic Targets Using Hybrid E-Pulse Method

Abstract—Radar scattered time domain response can be modeled by natural poles using singularity expansion method (SEM) in resonance region. In this paper, limitation of the conventional Extinction pulse method is brought out, and a hybrid of conventional Extinction pulse and auto-regressive (AR) method is proposed for robust discrimination of radar targets. A new target discrimination number (TDN) is suggested, which gives very good discrimination margin for enhanced decision process. The Hybrid Extinction pulse technique is applied on the free space targets as well as subsurface canonical metallic targets and the result obtained shows good discrimination margin. The free space target response was obtained using FDTD simulation and the subsurface target response was obtained using frequency domain measurement done for the targets buried under dry sand. 1

CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study

BACKGROUND: Cyclin E1 (CCNE1) is a potential predictive marker and therapeutic target in tubo-ovarian high-grade serous carcinoma (HGSC). Smaller studies have revealed unfavorable associations for CCNE1 amplification and CCNE1 overexpression with survival, but to date no large-scale, histotype-specific validation has been performed. The hypothesis was that high-level amplification of CCNE1 and CCNE1 overexpression, as well as a combination of the two, are linked to shorter overall survival in HGSC. METHODS: Within the Ovarian Tumor Tissue Analysis consortium, amplification status and protein level in 3029 HGSC cases and mRNA expression in 2419 samples were investigated. RESULTS: High-level amplification (>8 copies by chromogenic in situ hybridization) was found in 8.6% of HGSC and overexpression (>60% with at least 5% demonstrating strong intensity by immunohistochemistry) was found in 22.4%. CCNE1 high-level amplification and overexpression both were linked to shorter overall survival in multivariate survival analysis adjusted for age and stage, with hazard stratification by study (hazard ratio [HR], 1.26; 95% CI, 1.08-1.47, p = .034, and HR, 1.18; 95% CI, 1.05-1.32, p = .015, respectively). This was also true for cases with combined high-level amplification/overexpression (HR, 1.26; 95% CI, 1.09-1.47, p = .033). CCNE1 mRNA expression was not associated with overall survival (HR, 1.00 per 1-SD increase; 95% CI, 0.94-1.06; p = .58). CCNE1 high-level amplification is mutually exclusive with the presence of germline BRCA1/2 pathogenic variants and shows an inverse association to RB1 loss. CONCLUSION: This study provides large-scale validation that CCNE1 high-level amplification is associated with shorter survival, supporting its utility as a prognostic biomarker in HGSC

Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data

There is a need to develop and validate biomarkers for treatment response and survival in tubo-ovarian high-grade serous carcinoma (HGSC). The chemotherapy response score (CRS) stratifies patients into complete/near-complete (CRS3), partial (CRS2), and no/minimal (CRS1) response after neoadjuvant chemotherapy (NACT). Our aim was to review current evidence to determine whether the CRS is prognostic in women with tubo-ovarian HGSC treated with NACT.This article is freely available via Open Access. Click on the Publisher URL to access the full-text via the publisher's site

Bioremediation of toxic metal ions using biomass of <i style="">Aspergillus fumigatus</i> from fermentative waste

139-143Dried, nonliving, granulated biomass of Aspergillus fumigatus from fermentation industry was used for the removal of Cd2+, Co2+, Cu2+ and Ni2+ from solutions. Sorption studies showed sequestration (70-90%) of Cd2+ from solutions (0.1-4 mM). However, with increase in concentration, Cd2+ sorption efficiency decreased due to saturation of the biosorbent. Cu2+ binds most efficiently (72%) to the biosorbent followed by Cd2+ (61%), Co2+ (49%) and Ni2+ (37%). Metal removal from solutions containing a mixture of metal ions (Cd2+, Cu2+, Co2+, and Ni2+), which reflects the features of the polluted wastewaters and industrial effluents, was also efficient (90%) at lower concentrations (0.1 mM each). At higher concentrations (5 mM to 25 mM), Cu2+ removal was predominant (>70%) over other ions. The biosorbent was reusuable up to 5 cycles with a 50% loss of initial Cd2+ binding capacity. However, a significant loss of Cd2+ binding capacity was observed when biosorbent was immobilized in polyvinyl foam. Infrared spectra of the biosorbent preparation showed the involvement of alcohol/amine (OH/NH2) and CH-OH functional groups in metal binding. The present studies suggest that fungal biomass, a waste from fermentative industry, has the potential for removal/recovery of toxic metal ions from aqueous solutions

Safety and immunogenicity of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine in adults and children in Vellore, South India.

This open-label study assessed the safety and immunogenicity of two doses (14 days apart) of an indigenously manufactured, killed, bivalent (Vibrio cholerae O1 and O139), whole-cell oral cholera vaccine (SHANCHOL; Shantha Biotechnics) in healthy adults (n = 100) and children (n = 100) in a cholera endemic area (Vellore, South India) to fulfill post-licensure regulatory requirements and post-World Health Organization (WHO) prequalification commitments. Safety and reactogenicity were assessed, and seroconversion rates (i.e. proportion of participants with a ≥ 4-fold rise from baseline in serum vibriocidal antibody titers against V. cholerae O1 Inaba, O1 Ogawa and O139, respectively) were determined 14 days after each vaccine dose. No serious adverse events were reported during the study. Commonly reported solicited adverse events were headache and general ill feeling. Seroconversion rates after the first and second dose in adults were 67.7% and 55.2%, respectively, against O1 Inaba; 47.9% and 45.8% against O1 Ogawa; and 19.8% and 20.8% against O139. In children, seroconversion rates after the first and second dose were 80.2% and 68.8%, respectively, against O1 Inaba; 72.9% and 67.7% against O1 Ogawa; and 26.0% and 18.8% against O139. The geometric mean titers against O1 Inaba, O1 Ogawa, and O139 in both adults and children were significantly higher after each vaccine dose compared to baseline titers (P < 0.001; for both age groups after each dose versus baseline). The seroconversion rates for O1 Inaba, O1 Ogawa, and O139 in both age groups were similar to those in previous studies with the vaccine. In conclusion, the killed, bivalent, whole-cell oral cholera vaccine has a good safety and reactogenicity profile, and is immunogenic in healthy adults and children. Trial Registration: ClinicalTrials.gov NCT00760825; CTRI/2012/01/002354